Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.